Quarterly ResultAug 13, 2026, 05:09 PM
MapLight Therapeutics Q2 Net Loss $(60.2)M; R&D Expenses Up
AI Summary
MapLight Therapeutics reported a net loss of $(60.2) million for Q2 2026, a significant increase from $(29.8) million in Q2 2025, driven by higher research and development expenses. The company's accumulated deficit reached $481.4 million as of June 30, 2026. Despite ongoing losses, MapLight believes its existing cash, cash equivalents, and investments of $351.3 million will fund operations for at least twelve months. The company also made changes to its real estate portfolio, including terminating one lease early and entering a new one.
Key Highlights
- Q2 2026 net loss was $(60.2) million, up from $(29.8) million in Q2 2025.
- H1 2026 net loss was $(120.9) million, up from $(52.2) million in H1 2025.
- Research and development expenses rose to $53.4 million in Q2 2026 from $26.8 million in Q2 2025.
- Cash, cash equivalents, and investments totaled $351.3 million as of June 30, 2026.
- Accumulated deficit reached $481.4 million as of June 30, 2026.
- Total assets decreased to $368.3 million from $479.5 million since December 31, 2025.
- Exercised early termination for Redwood City lease, effective September 2027.
- Entered new South San Francisco lease, commencing May 2027.
Price Impact
More from MPLT